Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study

Aim. The primary aim of this study was to evaluate the pharmacokinetic parameters and confirm the bioequivalence of drugs containing gidazepam, namely Gidazepam® (Valenta Pharm, Russia) and Gidazepam VIC (VIVA Pharm, Republic of Kazakhstan), after a single administration of 1 tablet (50 mg) to health...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Baskakov, A. V. Grigorev, A. A. Globenko, A. G. Shmelev, E. A. Kolmykova, A. V. Yastrebova, A. A. Sidorova, A. V. Kapashin, O. V. Kovchan, A. I. Bashkatova, M. A. Pasko
Format: Article
Language:Russian
Published: LLC “Publisher OKI” 2023-11-01
Series:Фармакокинетика и Фармакодинамика
Subjects:
Online Access:https://www.pharmacokinetica.ru/jour/article/view/386
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849248578188345344
author E. V. Baskakov
A. V. Grigorev
A. A. Globenko
A. G. Shmelev
E. A. Kolmykova
A. V. Yastrebova
A. A. Sidorova
A. V. Kapashin
O. V. Kovchan
A. I. Bashkatova
M. A. Pasko
author_facet E. V. Baskakov
A. V. Grigorev
A. A. Globenko
A. G. Shmelev
E. A. Kolmykova
A. V. Yastrebova
A. A. Sidorova
A. V. Kapashin
O. V. Kovchan
A. I. Bashkatova
M. A. Pasko
author_sort E. V. Baskakov
collection DOAJ
description Aim. The primary aim of this study was to evaluate the pharmacokinetic parameters and confirm the bioequivalence of drugs containing gidazepam, namely Gidazepam® (Valenta Pharm, Russia) and Gidazepam VIC (VIVA Pharm, Republic of Kazakhstan), after a single administration of 1 tablet (50 mg) to healthy volunteers under fasting conditions. The secondary aim was a comparative analysis of safety profiles (adverse events) after a single administration of the studied drugs.Materials and methods. An open, randomized, crossover, two-period comparative study of pharmacokinetics and bioequivalence with adaptive design was conducted in healthy volunteers. Blood sampling was performed 15 minutes before and 20 min, 40 min, 1 h, 2 h, 3 h, 3.5 h, 4 h, 4.5 h, 5 h, 6 h, 8 h, 12 h, 24 h, 48 h, and 72 h after drug administration. High-performance liquid chromatography-tandem mass spectrometry was used for the evaluation of gidazepam and its metabolite (desalkylgidazepam) concentration with the subsequent calculation of pharmacokinetic parameters.Results. From both formulations, gidazepam was quickly absorbed and biotransformed into an active metabolite. Studied drugs had similar pharmacokinetic profiles, as 90% confidence intervals for the ratio of geometric means for Cmax and AUC(0-72) were within the bioequivalence acceptance range of 80.00–125.00 %. No adverse events were recorded as a result of clinical, laboratory or instrument evaluations during the study.Conclusion. Study drugs are considered bioequivalent and show comparable tolerability after a single administration under fasting conditions.
format Article
id doaj-art-c957ff2caa6c4ffaaba5d4fcf7d2fa60
institution Kabale University
issn 2587-7836
2686-8830
language Russian
publishDate 2023-11-01
publisher LLC “Publisher OKI”
record_format Article
series Фармакокинетика и Фармакодинамика
spelling doaj-art-c957ff2caa6c4ffaaba5d4fcf7d2fa602025-08-20T03:57:48ZrusLLC “Publisher OKI”Фармакокинетика и Фармакодинамика2587-78362686-88302023-11-01039410310.37489/2587-7836-2023-3-94-103349Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence studyE. V. Baskakov0A. V. Grigorev1A. A. Globenko2A. G. Shmelev3E. A. Kolmykova4A. V. Yastrebova5A. A. Sidorova6A. V. Kapashin7O. V. Kovchan8A. I. Bashkatova9M. A. Pasko10Yaroslavl regional clinical narcological hospitalCSU “Analytical Spectrometry”“Valenta Pharm” JSCYaroslavl regional clinical narcological hospitalГБУЗ ЯО «Ярославская областная клиническая наркологическая больница»CSU “Analytical Spectrometry”CSU “Analytical Spectrometry”“Valenta Pharm” JSC“Valenta Pharm” JSC“Valenta Pharm” JSC“Valenta Pharm” JSCAim. The primary aim of this study was to evaluate the pharmacokinetic parameters and confirm the bioequivalence of drugs containing gidazepam, namely Gidazepam® (Valenta Pharm, Russia) and Gidazepam VIC (VIVA Pharm, Republic of Kazakhstan), after a single administration of 1 tablet (50 mg) to healthy volunteers under fasting conditions. The secondary aim was a comparative analysis of safety profiles (adverse events) after a single administration of the studied drugs.Materials and methods. An open, randomized, crossover, two-period comparative study of pharmacokinetics and bioequivalence with adaptive design was conducted in healthy volunteers. Blood sampling was performed 15 minutes before and 20 min, 40 min, 1 h, 2 h, 3 h, 3.5 h, 4 h, 4.5 h, 5 h, 6 h, 8 h, 12 h, 24 h, 48 h, and 72 h after drug administration. High-performance liquid chromatography-tandem mass spectrometry was used for the evaluation of gidazepam and its metabolite (desalkylgidazepam) concentration with the subsequent calculation of pharmacokinetic parameters.Results. From both formulations, gidazepam was quickly absorbed and biotransformed into an active metabolite. Studied drugs had similar pharmacokinetic profiles, as 90% confidence intervals for the ratio of geometric means for Cmax and AUC(0-72) were within the bioequivalence acceptance range of 80.00–125.00 %. No adverse events were recorded as a result of clinical, laboratory or instrument evaluations during the study.Conclusion. Study drugs are considered bioequivalent and show comparable tolerability after a single administration under fasting conditions.https://www.pharmacokinetica.ru/jour/article/view/386gidazepampharmacokineticsbioequivalencebenzodiazepines
spellingShingle E. V. Baskakov
A. V. Grigorev
A. A. Globenko
A. G. Shmelev
E. A. Kolmykova
A. V. Yastrebova
A. A. Sidorova
A. V. Kapashin
O. V. Kovchan
A. I. Bashkatova
M. A. Pasko
Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study
Фармакокинетика и Фармакодинамика
gidazepam
pharmacokinetics
bioequivalence
benzodiazepines
title Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study
title_full Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study
title_fullStr Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study
title_full_unstemmed Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study
title_short Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study
title_sort study of the pharmacokinetic profile of the medicinal product gidazepam r tablets 50 mg in a bioequivalence study
topic gidazepam
pharmacokinetics
bioequivalence
benzodiazepines
url https://www.pharmacokinetica.ru/jour/article/view/386
work_keys_str_mv AT evbaskakov studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT avgrigorev studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT aaglobenko studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT agshmelev studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT eakolmykova studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT avyastrebova studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT aasidorova studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT avkapashin studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT ovkovchan studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT aibashkatova studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy
AT mapasko studyofthepharmacokineticprofileofthemedicinalproductgidazepamtablets50mginabioequivalencestudy